Latest News and Press Releases

Umsögn Bandaríska lyfjaeftirlitsins (FDA) á að liggja fyrir á seinni helmingi ársinsStelara (ustekinumab) er notað til meðferðar við ýmsum ónæmis- og bólgusjúkdómum Alvotech (NASDAQ: ALVO) og...

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory...

The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory...

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s...

Bandaríska lyfjaeftirlitið (FDA) hefur staðfest að frestur þess til að afgreiða umsókn um leyfi til markaðssetningar AVT02 sem líftæknilyfjahliðstæðu við Humira sé til 13. apríl 2023FDA hefur lokið...

U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023FDA has completed review of Alvotech’s...

Í tilkynningu sem birtist í morgun kom fram að Alvotech hefði gengið frá fjármögnun í formi víkjandi skuldabréfa með breytirétti í almenn hlutabréf. Heildarfjárhæð er um 10 milljarðar króna (70...

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million,...

Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million,...

Alvotech (NASDAQ: ALVO) tilkynnti í dag að fyrirtækið hefði gengið frá fjármögnun að fjárhæð um 8,5 milljarðar króna (59,7 milljónir Bandaríkjadala), miðað við núverandi gengi, í formi víkjandi...